Novo Nordisk's pricing approaches from the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, that has accused the company of selling price gouging, stating the stark distinction concerning U.S. rates and people in Europe and copyright. are scheduled to acquire surgical